Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Adial Pharmaceuticals ( (ADIL) ) is now available.
Adial Pharmaceuticals has entered into a new Purchase Agreement with Alumni Capital LP, allowing the company to sell up to $5 million of newly issued shares, with the potential to increase to $10 million, at its discretion. This agreement provides Adial Pharmaceuticals with strategic flexibility in managing capital and funding operations, potentially impacting its market positioning by enabling investments in strategic opportunities, expanding staffing and capabilities, and supporting general corporate purposes.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. is a company involved in the pharmaceuticals industry, focusing on the development of therapeutic products. The company’s market focus is primarily on addressing unmet medical needs and developing treatment options for various health conditions.
YTD Price Performance: -39.25%
Average Trading Volume: 173,035
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.24M
Find detailed analytics on ADIL stock on TipRanks’ Stock Analysis page.
